



## Repair Therapeutics to Participate in Two Upcoming Investor Conferences

November 7, 2022

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Nov. 7, 2022-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:

### H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference

Date: Monday, November 14, 2022

Time: 10:00 a.m. Eastern Time

Location: Virtual

### Piper Sandler 34th Annual Healthcare Conference

Date: Tuesday, November 29, 2022

Time: 3:00 p.m. Eastern Time

Location: New York, NY

A live webcast of the fireside chats can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcasts will be archived on the Company's website for at least 90 days.

### About Repair Therapeutics, Inc.

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development partnered with Roche; RP-2119, a Polθ inhibitor program in ongoing IND-enabling studies; as well as several additional, undisclosed preclinical programs. For more information, please visit [reparerx.com](http://reparerx.com).

SNIPRx® is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221107005156/en/): <https://www.businesswire.com/news/home/20221107005156/en/>

### Repair Contact:

Robin Garner  
Executive Director and Head of Investor Relations  
Repair Therapeutics Inc.  
[info@reparerx.com](mailto:info@reparerx.com)

### Investors:

Matthew DeYoung  
Argot Partners  
[repair@argotpartners.com](mailto:repair@argotpartners.com)

### Media:

David Rosen  
Argot Partners  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)  
212-600-1902

Source: Repair Therapeutics Inc.